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Abstract
Diets, through multiple mechanisms, cause significant impact on human health and disease
etiology; proposed modes of action include modulation of non-coding RNAs and influences on
the gut microbiome. Specifically, phytochemicals change human miRNA expression thereby
impacting gut microbiome and/or increasing host immune functions. Apiaceous and cruciferous
vegetables have been linked to decreased chronic inflammation, which is closely related with the
host immune system, yet it is not investigated how these two classes of vegetables influence the
colonic miRNA profile. In this study, therefore we aimed to determine the effects of short-term
feeding of broccoli and carrot to infants on fecal miRNA. Three experimental groups were
included: (1) control group (CON); (2) carrot group (CRT); and (3) broccoli group (BROC).
Participants began the five-day study at six months of age. The puree diets (either broccoli or
carrot puree) were introduced from Day 1 through Day 3 (i.e., 3 consecutive days: 2 oz per day).
During the intervention period (Day 1 - Day 3), the CON group participants continued
consuming breast milk and/or formula only. Diapers with stool were collected on Day 0, Day 2,
and Day 4. Fecal RNA was isolated and then miRNA expression was profiled using the
NanoString nCounter platform. Additionally, we subjected the miRNA results to Ingenuity
Pathway Analysis (IPA) and Gene Ontology Protein Analysis Through Evolutionary
Relationships (PANTHER) to predict enriched biological functions/molecular functions in
broccoli- and carrot-fed infants. Compared to the CON group, 22 miRNAs and 20 miRNAs
passed our criteria to be considered ‘differentially expressed’ from the CRT and BROC
intervention groups, respectively. In our miRNA target prediction analyses, using IPA, a total of
132 potential mRNA target transcripts were identified in the CRT group. Similarly, in the BROC
group, a total of 101 potential mRNA target transcripts was predicted. In the subsequent

PANTHER analyses, ‘Positive regulation of cellular response to macrophage colony-stimulating
factor stimulus’ and ‘Positive regulation of response to macrophage colony-stimulating factor’;
‘Interleukin-1, type I, activating receptor activity’; ‘Interleukin-1 receptor activity’; and
‘Interleukin-1 receptor binding’ were found to be most significantly enriched in the CRT infants.
On the other hand, in the BROC group, ‘Negative regulation of natural killer cell differentiation
involved in immune response’; ‘Regulation of natural killer cell differentiation’; ‘Interleukin-1,
type I, activating receptor activity’; ‘Interleukin-1 receptor activity’; and ‘Interleukin-1 receptor
binding’ were enriched the most. Overall, our study provides evidence that CRT and BROC
intervention impacts human infants’ miRNAs and may lead to overall benefits in their immune
system likely through different miRNA, predicted mRNA target transcripts, and
molecular/biological functions.
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Chapter 1
Review of Literature
What is MicroRNA?
Diet elicits significant impacts on human health and disease etiology with numerous
mechanisms thus far proposed; modulation of non-coding RNAs is one of them (1). MicroRNAs
(miRNAs) are one class of small non-coding RNAs (ncRNAs) and are mostly 20-22 nucleotides
in length. MiRNAs are the most abundant class of non-coding RNAs; these small RNAs inhibit
gene expression at the post-transcriptional level (2). Specifically, miRNAs are able to repress the
translation process of mRNA into proteins via perfect and/or imperfect base-pairing binding
thereby inducing mRNA degradation. As it is estimated that approximately one third of all
human genes is impacted by this class of small RNAs, it is not surprising that miRNAs play
pivotal roles in key biological processes; these include development, differentiation, cell death,
and proliferation (3).

Biogenesis of MicroRNAs
Small ncRNAs can be divided into a few sub-classes: short interfering RNAs, miRNAs, Piwiinteracting RNAs, repeat-associated small interfering RNAs, natural antisense transcript-derived
siRNA, trans-acting siRNA, and tiny ncRNAs (4). MiRNAs are the largest class in human tissues,
and are produced by a collective machinery of RNase III proteins [i.e., Drosha, and Dicer (5)]. In
humans, most miRNAs are encoded in intron regions, while some are present in exon regions (6).
Precise miRNA promoters for most miRNAs have been identified through collective analyses of
CpG islands and RNA sequencing data (7). MiRNAs often have multiple transcription start sites
(7)

, and may occasionally have distinct promoters from their host genes (8).
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Primary transcripts (also known as pri-RNA) are generated by RNA polymerase II, resulting
in short hairpin RNAs (pre-miRNAs) which will form secondary structures to yield mature
miRNAs (9; 10). After transcription, pre-RNAs undergo maturation steps to result in production of
miRNAs via the canonical pathway. Processing in the nucleus of pre-miRNAs is mediated by an
RNase III protein (Drosha), to predetermine the mature miRNA sequence via specific RNA
cleavage (11; 12). Once translocated to the cytoplasm, other cytoplasmic RNase III proteins (i.e.,
Dicer) act on the pre-RNA to release a mature double-stranded miRNA (13; 14). Post Dicer
processing, double-stranded miRNAs are unwound and “activated” via the incorporation into
RNA-induced silencing complex (RISC). Association with RISC allows for the silencing
capability of miRNA on target mRNA (15).
In addition to the canonical pathway of miRNA biogenesis, there is a non-canonical pathway;
which occurs when cells are deficient in DiGeorge syndrome critical region 8 (DGCRB), Drosha
or Dicer, where miRNA can be produced in a microprocessor-independent manner (16; 17). The
non-canonical pathway starts with the bypass of the Drosha-mediated processing step, and the
pre-RNA is generated through mRNA splicing; this process bypasses the transcription-generated
short hairpin RNAs (18). After the bypass, the pre-miRNA continues in the latter steps of the
canonical pathway (19). However, most miRNAs are produced by the canonical pathway, and
those produced by the non-canonical pathway tend to be low in number (5).

Control Points of MicroRNAs
There are multiple control points of miRNA biogenesis to fine-tune their expression and to
control biological functions. Although not fully understood, several regulatory factors have been
proposed thus far. The first possible regulatory mechanism includes Drosha binding proteins,
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which either positively or negatively modulate Drosha-mediated processes (20; 21). Another
possible control point relates to Drosha/DGCRB expression, which has been shown to alter
expression levels of miRNA (22; 23). Expression of exportin-5 could also modulate levels of
miRNAs; the exportin-5 is responsible for transport of miRNAs from nucleus to cytoplasm (24).
In the cytoplasm, Dicer binding proteins [i.e., TAR RNA binding protein and protein kinase
RNA activator] may regulate miRNAs through impacting the RISC assembly (25; 26).
Additionally, studies suggest that epigenetic controls contribute to miRNA regulation as well (27).
Specifically, miRNAs may be regulated through epigenetic control of multi-drug resistance-1,
where miRNAs could be directly repressed (28). Lastly, genetic single nucleotide morphisms
(SNPs) within the miRNA may alter the processing efficiency (29).
Although there is convincing evidence showing that miRNA play a role in post-transcriptional
regulations, specific mechanisms by which miRNAs control mRNA expression is still not fully
understood. One possible mechanism is that miRNAs may inhibit mRNA initiation by interfering
with the recognition of M7G-cap (30). Additionally, promotion to drop-off ribosomes by miRNA
was a proposed mechanism of mRNA repression (31). Another proposed mechanism is through
inhibition of actively translating polyribosomes (32). Lastly, miRNA-induced deadenylation may
possibly result in mRNA decay in P-body, high levels of which are found in the components of
mRNA decay pathway (33).
In the following sections we discuss evidence of the potential for dietary elements, and their
constituents, to regulate miRNA, and thereby influence target mRNA expression. As specific
mechanisms between miRNA and mRNA remain relatively unknown, the mechanistic influence
of diet remains unclear as well. Little is known of how miRNAs are impacted by diet, and of
potential targeted regulatory mechanisms of dietary constituents. Further research is needed to
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identify and solidify the mechanisms of miRNA control on mRNA, as well as the target
mechanisms impacted via dietary interventions.

Effects of Vegetables and Their Bioactives on MicroRNA
Phytochemicals are a diverse group of plant-derived bioactive compounds, including but not
limited to: polyphenols (i.e., flavonoids), carotenoids, glucosinolates, phytosterols, and allicins
[reviewed in (34)]. In addition, plant secondary metabolites (e.g., polyphenols) are phytochemicals
found in many plant foods, and are the most abundant source of antioxidants within the diet (35;
36)

. Dietary sources of each phytochemical category are included in Table 1s.
Accumulating evidence shows that dietary constituents influence miRNA expression, thereby

resulting in an array of downstream mRNA expression changes. Specifically, polyphenols in
fruits and vegetables alter miRNA expression. Phenolic constituents from mango were found to
modulate inflammation by regulating the expression of miR-126. Kim et al. demonstrated that
mango bioactives increased miR-126 expression which in turn suppressed the
phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR)/protein kinase B
(AKT) signaling axis (37). Another study showed that pomegranate ellagitannins and
anthocyanins upregulated miR-126 expression and suppressed PI3K signaling, thereby reducing
mucosal inflammation in carcinogen-treated rats (38). Last, blueberries, rich in polyphenols,
showed an inhibition of atherosclerosis-related miRNAs (i.e., miRNAs miR-21, miR-146a, and
miR-125b) when looking at the effect of polyphenol fractions in inflammation among RAW
264.7 cells (39). In the context of inflammation, polyphenols from green tea (i.e., catechins)
modulate the miRNA profile in white adipose tissue in mice fed a high-fat diet. Specifically, in
adipose tissue, miR-335 is known to be upregulated by TNF-α, a proinflammatory cytokine(40).

4

However, the TNF-α-mediated upregulation of miR-335 in adipocytes was inhibited through
catechins in green tea extract, and thereby reduced mRNA expression associated with insulin
resistance and lipid metabolism (e.g., Insr, Irs1, Sirt1, and Foxo1). Thus, it is indicated that
obesity leads to a pro-inflammatory state, and gene expression profiles associated with insulin
resistance are counteracted by green tea extract catechins via miRNA regulation and increased
lipolysis (40).
In addition to polyphenols, in a recent study, Slaby et al. found that three miRNAs (miR-155,
miR-23b, and miR-27b) were affected by iberin and sulforaphane (from the isothiocyanate class
of dietary bioactives) in colon epithelial cell lines (NCM460 and NCM356)(41). This study
showed possible roles of miRNAs in chemoprevention through targeting multiple genes
harboring SNPs (e.g., AGTR1, TNFAIP2, and SIRT5). Interestingly, DICER1, a gene involved
in the generation of miRNAs, was predicted as a target of miR-23b and was significantly
associated with decreased risk of sporadic colorectal cancer (41). Similarly, in a recent study,
butyrate, a metabolite of dietary fibers, was shown to regulate miRNAs; there was a reduction of
miR-106b, which may be involved in inhibition of LT97 colon adenoma cell proliferation(42).
The modification of miR-106b expression might contribute to the induction of cell cycle
regulatory proteins, like p21, as a mechanism of chemoprevention (42). These studies reinforce
the idea that dietary bioactives may not only influence colonic miRNA expression through their
direct modulation, yet also influence secondary metabolites produced by gut microbiome (e.g.,
butyrate).
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Gut Microbiome and Health
The human gut microbiome consists of over 100 trillion bacteria, fungi and viruses. This
plethora of microbes contributes more than 150 times more genetic information to the host than
the human genome itself (43), playing a key role in host health and diseases through this genetic
information. Advances in technology have improved the exploration of the human microbiome,
allowing for the categorization of the gut microbiome per operational taxonomic (OTUs) units
based on bacterial 16S ribosomal DNA. Now, vast studies are generating a map of the entire
metagenome to better understand functional signatures of the gut microbiome, and assess one’s
health status [i.e., Crohn’s disease (44)]. Diet is one of multiple factors contributing to the
functional signatures of the gut microbiome. For instance, studies show long-term, high-fiber
dietary exposure influences the gut microbiome in healthy young participants (45) and elderly
participants (46), supporting the notion of diet as an important contributor to the health of the
host’s gut microbiome.

Types of fibers and dietary sources
Dietary fibers have two subcategories, non-fermentable/insoluble and fermentable/soluble
forms, which have varying impacts on the health of the host. The division of fibers is based off
of differing physiochemical characteristics [e.g., origin, solubility and viscosity, fermentability,
and chemical structure (47)]. Both soluble and insoluble dietary fibers have beneficial
physiological effects on the host [e.g., body weight management (48)].
Soluble fibers (e.g., pectin, guar gum, and some inulin) are present in whole grains, legumes,
seeds and nuts, and some fruits and vegetables (e.g., carrots, apples) (49). One of the defining
physiochemical characteristics of soluble fibers includes viscosity, which slows absorption of
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nutrients in the intestine [e.g., glucose and lipids (47)] by creating a gel-like form. The capability
of soluble fiber (e.g., pectin) to slow the absorption of glucose has been shown to aid
preventative measures against metabolic diseases by controlling blood glucose levels (50).
Insoluble dietary fibers [e.g., celluloses, hemicellulose, and fructans (51)] are present in nuts,
beans, some whole grains (e.g., whole wheat flour and brown rice), and vegetables (52; 53). The
defining physiochemical characteristics of insoluble fiber include a bulking effect and
fermentation by the gut microbiome. Insoluble dietary fiber fermentation by the host gut
microbiome produces short-chain fatty acids (SCFAs) as secondary by-products, aiding in a
healthy microbial composition within the host gut microbiome (47). SCFAs are critical to the
health of the host due to their potential immunological influences [e.g., butyrate’s capability to
increase expression of antibacterial and host defense genes (54)]. A fiber-deprived gut
microbiome has shown to increase disease susceptibility due to a reduction in protective mucus,
which is utilized as a defense layer to block pathogens from entering the system (55), confirming
the beneficial impact of fiber on the health of the host.
Prebiotics were originally defined as “non-digestible compounds that, when consumed,
induce changes in composition and/or activity of the gastrointestinal bacteria, thus causing
benefit(s) upon host health” (56). Prebiotics include, but are not limited to, insoluble fibers.
Consumption of prebiotics (e.g., β-glucan, xylooligosaccharides, and pure inulin) has shown to
influence gut microbiota diversity and to increase production of SCFAs (52; 57; 58; 59). Positive
functional characteristics of prebiotics have been reported including, but not limited to: (a)
selective fermentation, (b) modulation of gut pH, (c) fecal bulking, (d) the prevention of gut
colonization by pathogens, and (e) the control of putrefactive bacteria, thus reducing the host’s
exposure to toxic metabolites (60).
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Production of SCFAs
SCFAs are produced by the gut microbiota through the fermentation of carbohydrates (50; 52)
and other non-absorbable nutrients (57; 59). The most abundant SCFAs include acetate, propionate,
and butyrate (61; 62), and represent 90-95% of all SCFAs produced in the colon (50; 58; 59). SCFAs
are utilized by downstream bacterial species (cross feeding) and/or directly by the host as
nutrient sources. Specifically, butyrate was frequently reported to be involved in other functions
such as immune regulation (63), cell growth (64; 65), intestinal barrier function (66), and ion transport
(67)

.

Effects of dietary fibers on epithelial barrier functions
The human intestine is a tubular organ, with the outer-most layer made of muscular tissue and
the inner-most layer consisting of a single layer of enterocytes interfacing between the host inner
tissue and the exterior intestinal environment. The single layered enterocytes are concatenated
through tight junctions (TJs) to form a defense for food-borne pathogens or other ingested toxic
compounds (68). The construction of TJs is maintained by enterocytes’ histological development
and signaling pathways, such as tumor necrosis factor-α (69). Without this maintenance, TJs are
the attack point for pathogenic bacteria to invade the host, resulting in permeability and leading
to destructive intravenous electrolyte exchange, microbial dysbiosis, and diarrhea (69).
Dietary fibers influence epithelial barrier functions through the production of SCFAs,
specifically butyrate. Butyrate has a beneficial effect on epithelial barrier function, and is known
to even nourish TJs (e.g., beta defensin, cingulin, ZO-1 and ZO-2 proteins) in chicken jejunal
and cecal explants (70). It is suggested that butyrate enhances the TJs through activating
Akt/mTOR pathways and ATP replenishment (71). Another potential function of dietary butyrate
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includes the repression of interleukin 10 (IL-10) receptor-dependent claudin-2, thereby
promoting barrier function by repressing the leak-flux mechanism responsible for diarrhea (72).

Anti-inflammatory effects of dietary fibers
The gut functions as one of the largest immune systems in humans, with physical (i.e., barrier
function) and biochemical defenses (73). Once triggered, the pro-inflammatory response is the
primary reaction to pathogens (74). Cells are then differentiated into multiple sub-types of
immune cells as a natural response (75). These epithelial cells are constantly encountering
pathogens and may frequently activate the immune response, resulting in immunologic diseases
[e.g., inflammatory bowel disease (IBD) and autoimmune diseases (76; 77)]. Anti-inflammation
(i.e., inhibitor of excessive inflammation) is needed to maintain immune homeostasis.
Butyrate is known to act as an anti-inflammatory through its modulation of cytokine production,
kinase activity, and immune-associated signaling pathways. Butyrate has been linked to multiple
anti-inflammatory mechanisms, including the up-regulation of immunosuppressive IL-10 (78),
nuclear factor (NF)-κB (79), and histone deacetylase (80; 81). Thus, supplementation of butyrate
dense dietary fiber may counteract the severity of IBD and other inflammatory syndromes (79; 82;
83)

.

Phytochemicals and Gut Microbiome
The term ‘phytochemical’ broadly encompasses all plant-derived chemicals. However, the
term ‘phytochemical’ typically is used to refer to small non-essential nutrients with healthpromoting actions (84). About 90%-95% of phytochemicals reach the colon, and are transformed
by the resident colonic microbiota (85), yielding bioavailable metabolites. The absorption of
phytochemicals have proven beneficial to the health of the host, as being cardioprotective (86; 87),
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and protective against glucose toxicity (88). Additionally, there has been a link with an increase in
phytochemicals (i.e., polyphenols) and prevention in metabolic syndrome (89; 90), as well as a
potential link to phytochemicals (i.e., hesperidin) and beneficial effects on colorectal cancer (91).
Last, unabsorbed dietary phytochemicals can directly modulate the microbiota. For instance,
phenolic compounds from tea leaves inhibited growth and adhesion of Clostridium Spp., E. coli,
and S. Typhumurium (92).

Carotenoids and their impacts on gut microbiome
Carotenoids have been linked to a decreased risk of chronic diseases (93), and to the health of
the gut microbiome. The effect of carotenoids, commonly found in apiaceous vegetables, on the
gut microbiome has been examined previously in two studies. Ramos et al. analyzed the
carotenoid source of Tucumã oil and its effect on microbial diversity and SCFA production in
cows. Results indicated the use of Tucumã oil as a carotenoid source favorably shifted the gut
microbiome. (94). Comparatively, a long-term randomized control study in humans analyzed the
relationship between colonic mucosal bacteria and serum carotenoid concentrations. A shift in 11
operational taxonomic units were associated with higher serum carotenoid levels, as well as other
factors (e.g., body mass index, smoking, diet). Thus, indicating both behavioral and metabolic
factors may impact the bioavailability of carotenoids to the gut microbiome (93).

Glucosinolates and their impacts on gut microbiome
The effect of glucosinolates, sulfur-containing dietary compounds, on the gut microbiome has
only been examined previously in one study. This gap in literature is surprising, as their benefits
benefits against chronic disease, such as cancers, are well known (95; 96; 97). In this study,
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Kaczmarek et al. found β-diversity alterations, indicating that bacterial communities were
impacted by broccoli feeding(98). Additionally, broccoli consumption significantly altered a few
key metabolic pathways: endocrine system, transport and catabolism, and energy metabolism (98).
Clearly, further studies are warranted in the context of the disease preventive potential of
cruciferous vegetables through gut microbiome modulation.

Cruciferous Vegetables and Immune Functions
The consumption of cruciferous vegetables has many health benefits, as they are a good
source of glucosinolates and the SCFA butyrate when digested by gastrointestinal microbiota
(e.g., Eubacterium rectale). In a recent study looking at fiber fermentation by gastrointestinal
microbiota, vegetables within the cruciferous family (i.e., broccoli and cauliflower) ranked
among the highest in total dietary fiber, substrate disappearance during fermentation, and SCFA
production compared to other vegetables (i.e., carrot, celery, onion, radish, cucumber, and
lettuce). Specifically, broccoli and cauliflower provided a good source of butyrate, a SCFA(99).
Butyrate plays an essential role in immune defense via the maintenance of the epithelial barrier
function, as previously noted. This beneficial effect on the intestinal epithelial barrier has been
linked to therapeutic and preventive effects against a number of diseases [i.e., cardiovascular
disease (100), hypertension (101), inflammatory disorders (102; 103; 104), and metabolic diseases (105)].
These beneficial effects include, but are not limited to, maintaining TJs within the epithelial wall
(106)

, and mediating immune homeostasis via epithelial biosynthesis of retinoic acid (107). Thus,

cruciferous vegetables (i.e., broccoli) continues to suggest an essential role in immune functions
of an individual through the production of the SCFA butyrate via gastrointestinal microbiota
digestion.
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Additionally, cruciferous vegetables provide the main source of the glucosinolate class of
phytochemicals in the diet (108). Glucosinolates can be hydrolyzed into various secondary
metabolites (i.e., isothiocyanates) (109). With the link between cruciferous vegetables secondary
metabolites and therapeutic/preventive effects on a multitude of diseases, the inclusion of these
vegetables is vital in dietary intervention of the gut microbiome. More research on the impact of
broccoli on the gut microbiome via secondary metabolite production (e.g., isothiocyanates and
SCFA) is needed, as only one article has surfaced when searched. Specifically, the impact of
broccoli’s role in immune function via gut microbiome modulation is relatively unknown, which
is somewhat unexpected given its frequent consumption. However, the impact of the SCFA
butyrate on immune function via the maintenance of the epithelial barrier has been well
established in literature.

Apiaceous Vegetables and Immune Functions
Currently there is a gap in the literature regarding apiaceous vegetables and immune function,
however some evidence exists for a role in reduction of inflammation. Apiaceous vegetable
dietary constituents, such as falcarinol (FaOH) and falcarindiol (FaDOH, play a primary role in
this reduction of inflammation. In a recent study, Kobaek-Larsen et al. reported antiinflammatory potential of apiaceous vegetables; it was found that FaOH and FaDOH inhibit NFκB signaling and its downstream inflammatory markers (e.g., COX-2) (110). Further, it was
reported that FaOH reduces inflammation via modulating Nrf2 mRNA (111). Nrf2 is a
transcription factor that upregulates the expression of antioxidant, anti-inflammatory, and
cytoprotective enzymes (112). Additionally, in rats, FaOH and FaDOH modified intestinal
microbiota composition by influencing the growth of Lactobacillus reuteri and Turicibacter (113).

12

Further investigation is needed regarding the relationship between apiaceous vegetables and
inflammatory markers, especially in the context of gut microbial modulation.

Crosstalk Between Gut MicroRNA and Gut Microbiome: Implications in Infants
Studies have showed that the gut microbiota could be regulated by host-secreted miRNAs
and, at the same time, the gut microbiota may affect the host by modulating various host
miRNAs. To be specific, gut microbes and their metabolites possess a potential to regulate gene
expression in intestinal epithelial cells via miRNA modulation and activation of multiple
signaling pathways and diverse immune responses. This results in a bidirectional crosstalk
between gut miRNA and the gut microbiome (114). In line with this, germ-free antibiotic-treated
mice had significantly more fecal miRNA compared to controls with pathogen-free microbiota,
indicating that gut microbes contribute to a specific miRNA signature (115). In the study,
reduction of luminal miRNAs was associated with a shift in the gut microbiota. It was proposed
that host-produced miRNAs are exported into the intestinal lumen as exosomes that are able to
drive miRNA to the gut bacteria where they regulate bacteria gene transcription programs (115).
As discussed above, clearly the gastrointestinal microbiota is a key factor in optimizing
immunity; this is well accepted considering that diverse health benefits (in an array of disease
models) can be achieved via modulation of gut microbiome. The foundation of one’s gut
microbiome is contingent upon 1) acquiring microbiota via mother’s milk in infancy and 2) early
dietary habits (116). In adults, short-term dietary intervention studies may show change within the
microbiota, however maintaining microbial changes in a long-term intervention study has
previously been shown to be difficult (117). Therefore, it is vital to establish a healthy gut
microbiome as early as possible to ensure maximum health benefits throughout life (118). In the
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first years of life (i.e., years 1-3) the microbiota and immune system are not yet matured or
established (119), and therefore offer an opportune time to alter the gut microbiome via diet
intervention. Thus, infancy proves a critical age group to target food-based intervention in hopes
to reduce disease risk and increase immune function. Further, understanding the bidirectional
crosstalk between gut miRNA and the gut microbiome would broaden our knowledge as to how
the early establishment of the gut microbiome is mediated by host miRNAs, and if so, how diets
play roles into mediating host miRNA.
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Chapter 2
Methods
Specific Aim and Hypothesis
This study aimed to determine the effects of short-term feeding of broccoli and carrot to
infants on fecal miRNA. We hypothesized that broccoli and/or carrot would modulate fecal
miRNA expression profiles, thereby potentially targeting key mRNAs involved in innate
immunity.

Study Design
The study is a randomized controlled intervention design and each participant provided
baseline data prior to their respective vegetable intervention. By the time of recruitment,
participating infants were four to five months old thereby they could start the intervention (i.e.,
semi-solid vegetable food) at the age of six months. The justification for the intervention timing
is two-fold: (1) World Health Organization (WHO) recommends starting solid foods at the age of
six months (120), and (2) previous studies underscored the importance of the establishment of
healthy intestinal microbiota in the first three years of life (119). The participants were followed
for five days.
This study consisted of three intervention groups: (1) control group (CON); (2) carrot group
(CRT); and (3) broccoli group (BROC). The CON group participants consumed only breast milk
and/or formula, without any vegetables for the intervention period. This would be consistent with
the infant’s normal diet previously, as we excluded participants who had previous exposure to
solid foods. During the intervention period, the CRT group and BROC group consumed carrot
puree product and broccoli puree product, respectively, in addition to breast milk and/or formula.
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For the vegetable puree, commercially available, frozen, pureed baby food products were
purchased from Harvest to Highchair (Charleston, SC, USA). As the product was raw puree, the
company did not provide nutritional information on their product’s packaging. According to the
USDA database, 2 oz of raw broccoli provides 19 kilocalories, 1.5 g of total dietary fiber, 25.85
mg of calcium, 0.4 mg of iron, 175 mg of potassium, 49.05 mg of vitamin C, and 17.05 µg
vitamin A. A serving of 2 oz of raw carrots provides 23 kilocalories, 1.6 g of total dietary fiber,
18.75 mg of calcium, 0.17 mg of iron, 182.2 mg of potassium, 3.35 mg of vitamin C, and 475.5
µg vitamin A (121). Commercial baby food products were chosen for the study, rather than
preparing the diet in the lab, thereby providing consistent, well controlled products and
enhancing applicability of the study for the general public.
The study lasted a total of five days, starting on the participant’s sixth month of age marker.
On the first day (Day 0), diapers with fecal matter were collected for characterization of baseline
miRNAs. Also, a food recall for the past 10 days (Day -10 through Day 0) was collected; the
food recall was provided when subjects (in our study, parents of participating infants) agreed to
participate in the study. Through the food recall, information such as amount, types (i.e., breast
milk, formula or both), when, and how frequently the participating babies consumed breast milk
and/or formula, was recorded. The food recall example is shown in Figure 1.
The puree diets (either broccoli or carrot puree) were introduced from Day 1 through Day 3 (i.e.,
3 consecutive days: 2 oz per day). During the intervention period (i.e., Day 1 - Day 3), the CON
group participants continued consuming breast milk and/or formula only. The WHO
recommends complimentary food at age six to eight months to be offered 1-2 times a day (120).
Therefore, our study offered 2 oz of vegetable puree a day; this allows for participating babies to
consume the vegetable puree diets 1-2 times per day. All feeding information was collected

16

using our food recall form. The study design, diaper collection schedule, and dietary intervention
information are depicted in Figure 2. This thesis is apart of a larger research project, which
extends the intervention, diaper collection, and participants for a total of 30 days. Figure 2 shows
the study design for the larger project; however, this thesis stops on Day 4.

Participant Recruitment
Participants were recruited in the Northwest Arkansas region (Washington and Benton
counties, AR, USA) for one year (August, 2018- August, 2019). The recruitment was conducted
via online news publication (e.g., University of Arkansas News), posted flyers, notification to
local daycares, and personal recommendation. Inclusion criteria for participants included: four to
five months old at the time of enrollment; willing to avoid over-the-counter and/or prescription
medications; willing to exclude certain fruits, vegetables, and herbs from Day -10 through Day 8;
willing to comply with the study protocol; and no plan to travel during the study duration.
Exclusion criteria included: liver, kidney, or intestinal disorder history; necessary prescription
medications; necessary over-the-counter medications; known allergies and/or intolerances to
broccoli and carrots; plans to move out of Northwest Arkansas during the study period. If the
participants had started solid foods prior to the intervention period, they were excluded from the
study. The recruitment was not limited by milk source, breastfed nor formula fed infants. A total
of 14 participants were recruited. Two participants dropped out due to occurrence of illness, and
one participant failed to comply with the protocol, resulting in a total of 11 participants. The 11
participants were randomly assigned to three groups: CON (n=3), CRT (n=4), and BROC (n=4).
Participant demographics (i.e., ethnicity and sex) is provided in Table 2.
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Participant Compliance
As aforementioned, participant compliance was monitored using food recalls; each participant
received two food recall forms for (1) Day -10 through Day -1; (2) Day 0 through Day 4. The
first food recall aimed to gather information as to typical feeding patterns of the infants prior to
the study intervention. The second food recall tracked how much of the intervention vegetable
was consumed in addition to other diet consumption (e.g., breast milk and/or formula) during the
period. In addition, fecal collection questionnaires were provided for asked to record time of
diaper collection as well as stool sample conditions (e.g., consistency and color).

Stool Collection
Fecal collection was conducted in the best temperature sensitive way available for the study
and participants. Each participant received a cooler with frozen ice packs for diaper collection;
participants were instructed to keep the ice packs frozen until the day of the collection where
they would put them in the cooler. When a dirty diaper occurred, the participants were instructed
to put the diaper in a plastic zip-lock bag and placed in the cooler until the designated collection
time. All fecal samples given that day were collected, transferred to the lab, and then stored at 80°C until further analyses.

Fecal RNA Extraction
Fecal RNA from Day 0 and Day 4 was isolated using the RNeasy PowerMicrobiome kit
(Qiagen, Hilden, Germany). In short, 0.25 g of stool was placed into a PowerBead tube, and then
mixed with 650 μL PM1/βME at maximum vortex speed for 10 minutes. After, the tube was
centrifuged at 13,000 × g for two minutes and the supernatant was transferred to a clean
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collection tube. Next, 150 μL of IRS solution was incubated at 4°C for five minutes and
centrifuged at 13,000 × g for one minute. Avoiding the pellet, the supernatant was transferred to
a clean tube. A solution of 650 μL of PM3 and 650 μL of PM4 was added to each tube. The
resulting supernatant was added to a MB RNA Spin Column and centrifuged at 13,000 × g for
one minute; this step was repeated until all the supernatant had been processed through the spin
column. Next, 650 μL of PM5 was added to the MB RNA Spin Column and centrifuged at
13,000 × g for one minute. In the center of the column, 50 μL of DNase 1 solution was added
and incubated at room temperature for 15 minutes. After, 400 μL of solution PM7 was added and
centrifuged at 13,000 × g for one minute. Next, 650 μL of solution PM5 was added and
centrifuged for one minute. Then, 650 μL of solution PM4 was added and centrifuged. After
discarding the flow through, the MB RNA Spin Column was placed into a clean 2 mL collection
tube. Lastly, 50 μL of RNase-free water was added to the center of the filter membrane and
incubated for one minute. The water was centrifuged at 13,000 × g for one minute, and the RNA
extraction was completed. The quality of isolated RNA was assessed using the conventional
A260/280 ratio and the A260/230 ratio measurement (SpectraMax i3x; Molecular Devices,
Sunnyvale, CA, USA). RNA samples were stored in test tubes in -80°C.

Profiling Fecal MiRNAs
Once we confirmed that all extracted RNA samples had a 280/260 ratio of ≥ 1.9 and a
260/230 ratio of ≥ 1.8, extracted RNA was normalized to a single concentration (33 ng/µL) and
then loaded into 96-well plates. The 96-well plates were sealed and shipped on dry ice to the
University of Minnesota Genomic Center (Minneapolis, MN, USA). Fecal miRNA profiling was
performed using the NanoString nCounter platform (NanoString, Seattle, WA, USA). The pre-
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built panel for human miRNA (nCounter Human v3 miRNA panel) was used, in which a total of
827 different miRNA were analyzed.

Statistical Analyses and Bioinformatics Analyses
MiRNAs from Day 0 and Day 4 were analyzed using Nanostring nCounter platform to
examine impacts of short-term dietary intervention of the vegetables on fecal miRNA
expression. First, to ensure that differentially expressed miRNAs were due to dietary intervention
and not by other factors, such as infant growth, we normalized the miRNA expression data with
their respective baseline which is the data obtained at D0. After, the miRNAs differentially
expressed in BROC or CRT were separately compared to the CON by a two-tailed Welch’s t
test. A p-value of less than 0.05 was considered statistically significant (Microsoft Excel;
Microsoft, Redmond, WA, USA). Data are expressed as mean ± standard error of mean (SEM).
After, for the miRNA dataset, a short-list of differentially expressed genes (DEGs) was
generated, using the criteria of miRNA showing a p-value < 0.05 and fold change > ± 1.5. The
DEGs were subjected to the IPA software to predict potential mRNA targets, and potentially
affected signaling pathways in response to BROC or CRT intervention. After, the predicted
mRNA targets were subjected to PANTHER to assess over-represented, or under-represented
biological processes and molecular functions in response to BROC or CRT intervention
(available at pantherdb.org). We included the top 15 biological processes and molecular
functions based on fold enrichment for CRT and BROC.

20

Chapter 3
Results
Effects of CRT Intervention
Identification of differentially expressed miRNAs in response to CRT intervention
In order to explore impact of CRT intervention on colon miRNA profile, we conducted
miRNA expression profiling on infants’ fecal samples who were fed two ounces of carrots, per
day, over three days. Based on the criteria mentioned above to be considered differentially
expressed, a total of 22 miRNAs were included in our DEG list. Of the 22 miRNAs modulated,
14 miRNAs were up-regulated and 8 miRNAs were down-regulated. Those up-regulated by the
CRT intervention were miR-1253, miR-130a-3p, miR-146a-5p, miR-147a, miRNA-193-3p,
miR-3127-5p, miR-3144-3p, miR-365b-5p, miR-374c-5p, miR-376b-3p, miR-561-5p, miR-595,
miR-603, and miR-627-5p. Down-regulated miRNAs by CRT intervention were miR-200c-3p,
miR-2116-5p, miR-300, miR-320a-3p, miR-378b, miR-508-5p, miR-521, and miR-885-3p
(Table 3).

Computational analysis of miRNA from CRT intervention: prediction of target mRNAs
The twenty-two miRNAs considered differentially expressed were subjected to IPA analysis
in order to predict their downstream target mRNAs. Per IPA target prediction, eight miRNAs
(miR–130a-3p, miR-146a-5p, miR-147a, miR-193a-3p, miR-200b-3p, miR-320b, miR-378a-3p,
and miR-521) collectively targeted 132 mRNAs. It was predicted that some miRNAs targeted
only one mRNA (e.g., miR-147a and miR-521) while the others targeted more than one mRNAs
(e.g., miR-130a-3p, miR-320a-3p, miR-378b). Of note, it was predicted that miR-146a-5p targets
a total of 80 mRNA from CRT intervention, which is the majority of the 132 mRNAs predicted
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to be influenced by CRT. miR-193a-3p was predicted to target nine mRNAs [e.g., cyclin D1
(CCND1), E2F transcription factor 6 (E2F6), erb-b2 receptor tyrosine kinase 4 (ERBB4),
estrogen receptor 1 (ESR1), MCL1 apoptosis regulator, BCL2 family member (MCL1),
plasminogen activator, urokinase (PLAU), protein tyrosine kinase 2 (PTK2), and ribosomal
protein S6 kinase, 70kDa, polypeptide 2 (RPS6KB2)] whereas miR-200b targets 23 mRNAs
[BRACA1 associated protein 1 (BAP1), engulfment and cell motility 2 (ELMO2), erbb2
interacting protein (ERBIN), ERBB receptor feedback inhibitor 1 (ERRFI1), formin homology 2
domain containing 1 (FHOD1), forkhead box F2 (FOXF2), gem (nuclear organelle0 associated
protein 2 (GEMIN2), gse1 coiled-coil protein (GSE1), kelch-like family member 20 (KLHL20),
myristoylated alanine rich protein kinase C substrate (MARCKS), phospholipase C gamma
(PLCG1), protein phosphatase, Mg2+/Mn2+ dependent 1F (PPM1F), phosphatase and tensin
homolog (PTEN), protein tyrosine phosphatase non-receptor type 12 (PTPN12), protein tyrosine
phosphatase non-receptor type 13 (PTPN13), protein tyrosine phosphatase receptor type D
(PTPRD), arginine-glutamic acid dipeptise (RE) repeats (RERE), WASP family member 3
(WASF3), WD repeat domain 37 (WDR37), zinc finger E-box binding homebox 1 (ZEB1), zinc
finger E-box binding homebox 2 (ZEB2), and zinc finger protein, FOG family member 2
(ZFPM2)]. No mRNA targets were identified by IPA for the remaining 14 miRNAs (Table 3).

Gene Ontology prediction of targeted mRNAs in CRT intervention
The PANTHER over-representation tool was used to identify biological processes and
molecular functions that were over-represented in the identified target mRNAs. The top 15
identified biological processes and top 15 molecular functions of predicted target mRNAs in
CRT intervention group are shown in the Table 5 and Table 6, respectively. Eight over-
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represented biological processes had a fold enrichment greater than 100, with p <0.001.
Additionally, five over-represented mRNA molecular functions had a fold enrichment greater
than 60, with p <0.001. Of note, all of the top three molecular functions significantly overrepresented involved interleukin-1 activity, including ‘Interleukin-1, type I, activating receptor
activity,’ ‘Interleukin-1 receptor activity,’ and ‘Interleukin-1 receptor binding.’ The targeted
mRNA identified in our dataset are associated with ‘Interleukin-1, type I, activating receptor
activity’ included interleukin 1 receptor type 1 (IL1R1) and interleukin 1 receptor like 2
(IL1RL2). The identified target mRNAs, associated with ‘Interleukin-1 receptor activity’,
include interleukin 1 receptor accessory protein (IL1RAP), IL1R1, IL1RL2, and interleukin 1
receptor accessory protein-like 2 (IL1RAPL2) (Table 5). Lastly, molecular function ‘Interleukin1 receptor binding’ was associated with seven interleukin mRNAs. MRNAs identified include
toll like receptor 9 (TLR9), IL1RAP, interleukin 36 alpha (IL36A), interleukin 1 family member
10 (ILF10), interleukin 36 gamma (IL36G), interleukin 37 (IL37), interleukin 36 receptor
antagonist (IL36RN), and interleukin 36 betta (IL36B) as targeted mRNA from our dataset. All
biological processes and molecular functions were significantly different in terms of fold
enrichment (Table 5 and Table 6).

Effects of Broccoli Intervention
Identification of differentially expressed miRNA in response to BROC intervention
Similar to the CRT intervention, in order to identify global impacts of BROC intervention on
colonic miRNAs, we conducted miRNA expression profiling using fecal samples from infants
who received two ounces of broccoli, per day, over three days. Based on the criteria
aforementioned, a total of 20 miRNAs were included in our list. Of the 20 miRNAs modulated,
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nine miRNAs were up-regulated and 11 miRNAs were down-regulated. Those up-regulated by
the BROC intervention were: miR-146a-5p, miR-190b, miR-22-3p, miR-3934-5p, miR-409-5p,
miR-520f-3p, miR-548i, miR-573, and miR-612. Those down-regulated by BROC intervention
were: miR-205-5p, miR-2116-5p, miR-329-3p, miR-361-5p, miR-3613-3p, miR-4425, miR4443, miR-499a-3p, miR-503-3p, miR-579-5p, and miR-596 (Table 4).

Computational analysis of miRNA from BROC intervention: prediction of target mRNAs
Twenty miRNAs met the screening criteria for IPA analysis to predict target mRNAs. Six
miRNAs collectively targeted 101 mRNAs from our dataset. MiR-361-5p only targeted one
mRNA while others were predicted to interact with multiple transcripts (e.g., miR-22-3p
targeting five mRNAs [bone morphogenetic protein 7 (BMP7), ESR1, MYC associated factor
(MAX), peroxisome proliferator activated receptor alpha (PPARA), and serum response factor
(SRF)]. No targets were identified by IPA for the remaining 14 miRNAs (Table 4).

Gene Ontology prediction of targeted mRNAs in BROC intervention
Similarly, the PANTHER over-representation tool was utilized to identify biological
processes and molecular functions that were significantly over-represented by the predicted
mRNA targets in the BROC group. Table 7 and Table 8 display the top 15 enriched biological
processes and the top 15 molecular functions of predicted mRNAs in broccoli-fed infants. Eight
significantly over-represented mRNA biological processes had a fold enrichment greater than
100, with p <0.001. In particular, ‘Negative regulation of natural killer cell differentiation
involved in immune response’ and ‘Regulation of natural killer cell differentiation’, with
identified mRNAs peptidoglycan recognition protein 2 (PGLYRP2) and peptidoglycan
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recognition protein 1 (PGLYRP1), were found to be over-represented (Table 7). Additionally,
three over-represented mRNA molecular functions had a fold enrichment greater than 100, with
p <0.001; two molecular functions significantly over-represented, were involved with
interleukin-1 activity. These included ‘Interleukin-1, type I, activating receptor activity’ with
identified mRNAs IL1R1, IL1RAPL2, and ‘Interleukin-1 receptor activity’ with the identified
mRNAs being IL1RAP, IL1R1, IL1RL, and IL1RAPL2. Lastly, ‘Interleukin-1 receptor binding’
was over-represented with a fold enrichment of 94.35 and a p<0.001; identified mRNAs from
our dataset for ‘Interleukin-1 receptor binding’ included TLR9, IL1RAP, IL36A, ILF10, IL36G,
IL37, interleukin 36 receptor antagonist (IL36RN), and IL36B (Table 8).
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Chapter 4
Discussion
A global miRNA profiling analysis was conducted to determine effects of short-term feeding
of broccoli and carrot on infants’ fecal miRNAs. In both CRT and BROC intervention, miR146a-5p was upregulated and was predicted to target 80 mRNAs per the IPA target prediction
algorithm (Table 3 and Table 4). Functional characteristics of these predicted target mRNAs
include tumor suppression, immune response, and inflammatory regulation.
Regarding the immune response, the miR-146a-5p predicted to targeted signaling pathway is
involved with TLR4; it is well established that the TLR4 signaling pathway plays an important
role in activating the innate immune response (122). Similarly, TLR1 was a predicted target by
miR-146a-5p, which plays a critical role in pathogen recognition as well activating innate
immunity (123). Additionally, CRT also upregulated miR-130a-3p, which was predicted to target
CSF1 (Table 3); CSF1 is critical for innate immunity and inflammatory processes through its
capability to promote proinflammatory chemokines (123). These three predicted target mRNAs
(i.e., TLR1, TLR4, and CSF1) show the potential for dietary supplementation of carrots to
increase the innate immunity in infants. This is particularly important for infant participants, as
an increase in innate immunity may decrease the rate of early infection early on (124; 125; 126).
Other immune functions related miR-146a-5p’s target mRNAs include C-reactive protein
(CRP), complement factor H (CFH), component of inhibitor of NF-κB kinase complex (CHUK),
CD40 molecule (CD40), and TNF receptor associated factor 6 (TRAF6). CRP supports host
defense through recognition of pathogens and damaged cells of the host and to initiate their
elimination while CFH protein regulates host immune response through destroying pathogens,
initiation of inflammatory responses, and removal of debris from cells and tissues (123). In
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addition, CHUK (a target mRNA of miR-146a-5p) is known to participate in the canonical IKK
complex by NF-κB activation and phosphorylates inhibitors of NF-κB on serine residues. NF-κB
transitions to the nucleus and activates the transcription of hundreds of genes involved with
immune response, growth control, or protection against apoptosis (123). CD40 protein is
responsible for mediating a variety of immune and inflammatory responses; including T-cell
dependent immunoglobulin class switching, memory B cell development, and germinal center
formation (123). Last, TRAF6 may mediate CD40 signal, thus proving critical in immunoglobulin
production regulation (123). This evidence in literature collectively proposes that carrot
supplementation may aid in an infant’s capability to fight off disease after exposure, and could
benefit the infant’s immunity. As an upregulation of miR-146a-5p is predicted to impact these
genes directly, it is yet to be seen the reach of beneficial impacts enacted by these targeted
mRNAs.
CRT intervention may be related with tumor suppression as well. The miR-146a-5p (which
was upregulated by the CRT) was predicted to target mRNAs, C-C motif chemokine ligand 8
(CCL8), BRCA1 DNA repair associated (BRCA1), and cyclin dependent kinase inhibitor 3
(CDKN3). The role of CCL8 still remains relatively unknown, however an increase of CCL8
expression has been linked to multiple cancers (e.g., squamous cell (127), and cervical (128)). In
contrast, BRCA1 is well known to provide instructions for tumor suppression proteins, therefore
aiding in the maintenance of the rate of cell proliferation (123). Lastly, CDKN3 is related with cell
cycle regulation and is known to be abnormally expressed (e.g., deleted, mutated, or
overexpressed) in multiple cancers (123; 129; 130). In addition, in the context of cancer, predicted
target mRNAs of miR-147a-5p include MCL1 apoptosis regulator, BCL2 family member
(MCL1). MCL1 inhibits apoptosis in isoform 1, and its overexpression has been linked to lung

27

cancer progression and decrease survival rates (123; 131; 132). The miR-200c-3p, downregulated in
the CRT intervention, was predicted to target BRCA1 associated protein 1 (BP1) and PTEN.
Both of which act a tumor suppressors, regulating cell proliferation (123). As these predicted target
mRNAs are related with tumor development as well as progression (e.g., cell proliferation),
carrot supplementation has the potential to aid in preventing growth of tumors as infants’ bodies
continue to grow and mature.
Lastly, when comparing CRT to CON, there were multiple targeted mRNAs involved in
inflammatory processes through miRNA upregulation and downregulation. Upregulation of miR146a-5p by CRT intervention was predicted to target multiple interleukins and cytokines (Table
3), as well as other supportive mRNAs [e.g., chemokine receptor 3(CCR), Fas associated via
death domain (FADD), interferon regulatory factor 5 (IRF5), nitric oxide synthase 2 (NOS2),
and signal transducer and activator of transcription 1 (STAT1)]. FADD, IRF5, and NOS2 are
involved in the synthesis and development of various interleukins and T-cells (123). Targeted
mRNA CCR is associated with acute inflammatory response (133). STAT1 is associated with the
IL-17 pathway, and interferon-alpha/beta and interferon-gamma signaling pathways. These
pathways are critical in the immune defense against bacteria and viruses (123). Additionally, the
upregulation of miR-130a-3p was predicted to target CSF1, which promotes the release of
proinflammatory chemokines (123). These results suggestion the role of key miRNAs influenced
by CRT may play in regulating inflammation, which is further supported by the previously
established anti-inflammatory effects of apiaceous vegetables, such as carrots (110; 134).
PANTHER analysis identified multiple biological processes and molecular functions,
changed in the CRT intervention. Specific to immune function, the biological process ‘Positive
regulation of interleukin-12 biosynthetic process’ had a significant fold change, and was
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predicted to be influenced by mRNAs, TRAF6, LBT, TLR4. Interleukin 12 has an essential role
in promoting T helper cell responses, therefore is found in cell-mediated immunity (135).
Likewise, many predicted molecular functions support these immunological processes
potentially influenced by CRT intervention. For example, the predictions of ‘Interleukin-1, type
I, activating receptor activity’ targeted by IL1R1 and IL1RL2, ‘Interleukin-1 receptor activity’
targeted by IL1RAP, IL1R1, IL1RL2, and IL1RAPL2, and ‘Interleukin-1 receptor binding’
targeted by TLR9, IL1RAP, IL36A, ILF10, IL36G, IL37, IL36RN, and IL36B. The interleukin 1
family (e.g., IL18, IL36, IL37, IL38) have been recognized for their pivotal roles in
inflammation and immunity. Specifically, Interleukin 1 family members participates in
therapeutic and preventative measures in autoimmunity and auto-inflammation (136). These
predicted biological processes and molecular functions display the potential of CRT to influence
inflammatory processes.
Additionally, multiple biological processes involving macrophages were predicted to be
influenced. Biological processes ‘Positive regulation of cellular response to macrophage colonystimulating factor stimulus,’ Positive regulation of response to macrophage colony-stimulating
factor,’ ‘Regulation of response to macrophage colony-stimulating factor,’ and ‘Regulation of
cellular response to macrophage colony-stimulating factor stimulus’ were predicted to be
targeted by mRNAs, CSF1 and TLR4. Macrophages are central to the innate immune system,
and plays a role in inflammation through release of cytokines (137). The prediction of these four
macrophage biological processes are supported by the prediction of cytokine molecular
functions. Molecular function ‘Cytokine receptor activity’ was related with IL12RN2, IL1RAP,
CCR3, CXCR4, IL1R1, IL1RL2, and IL1RAPL2. Collectively, these biological processes and
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molecular functions suggest the potential of CRT intervention to impact the human infants’
innate immunity.
In the BROC intervention, we found a total of 20 miRNAs differentially expressed in fecal
samples. Unique to the BROC intervention, we observed a downregulation in miR-205-5p.
When subjected to IPA analysis, predicted targeted mRNAs of miR-205-5p included ATP1A1,
INPPL1, and PTEN; as previously discussed, PTEN is a tumor suppressor (which can target by
miR-200c-3p in the CRT intervention). This is unsurprising, as miRNAs have multiple targets,
and multiple miRNAs can target a single mRNA (138). The three mRNAs predicted to be targeted
by miR-205-5p proposes broccoli’s potential capability to impact multiple systems within the
body (i.e., Na+/K+ ATPase protein pump, insulin regulation, and tumor suppression), thereby
the potential to have protective or therapeutic effects on multiple diseases (e.g., cancer, blood
pressure, diabetes). ATP1A1 is a gene that produces one part of Na+/K+ ATPase protein pump;
this pump is particularly important in adrenal glands and influences blood pressure in the body
(123)

. Additionally, INPPL1 encodes SH2-containing 5'-inositol phosphatase, which aids in the

regulation of insulin (123). Together, these target mRNAs show the potential of miRNAs
supporting broccoli’s impact on metabolic diseases (e.g., diabetes, hypertension) after
phytonutrient absorption by the gut microbiome (139; 140). As childhood metabolic diseases are on
the rise world-wide, the beneficial effects of INPPL1 and ATP1A1 on insulin regulation and
blood pressure may aid in the health of infants through dietary interventions. This would be an
important next step for future studies, in order to fully understand the reach of BROC
intervention of the long-term health of an infant.
Lastly, when BROC intervention had a predicted increase in immunoregulatory mRNAs,
indicating a potential role in the immune system of the infant. Of note, the BROC also
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upregulated miR-146a-5p, which targeted a total of 80 mRNA when subjected to IPA. As
expected, the predicted target mRNAs were identical with those identified in the CRT
intervention (e.g., TLR4, TLR1, CSF1, CRP, CFH, CHUK, CD40, and TRAF6) and many are
discussed in detail above. Of note, IRAK1 is a putative serine/theonine kinase that is associated
with interleukin-1 receptor, which is critical in innate immune response against pathogens (123).
Additionally, CCR, FADD, IRF5, NOS2, and STAT1, indicate potential impacts of broccoli
supplementation on inflammatory responses. In addition, the BROC group showed decreased
expression of miR-361-5p when compared to the CON, which was predicted to target activation
induced cytidine deaminase (AICDA). AICDA is a protein involved in somatic hypermutation,
gene conversion, and class-switch recombination of immunoglobulin genes (123). Therefore, miR361-5p may play a role in helping the immune system adapt to foreign elements through
targeting AICDA. Although broccoli’s influence on inflammation is well studied, this is the first
time it has been predicted in human infants.
In the PANTHER analyses, BROC intervention recognized the enrichment of biological
processes: ‘Negative regulation of natural killer cell differentiation involved in immune
response,’ ‘Negative regulation of natural killer cell differentiation,’ and ‘Regulation of natural
killer cell differentiation involved in immune response.’ Natural killer cells are vital in our
body’s defense system, and are utilized to attack infections and the growth of tumors (141). As
natural killer cell differentiation depends on T and B cells (142), multiple molecular functions
identified support this process; For example, ‘Lipopolysaccharide immune receptor activity’ is
related with mRNAs TLR4 and PTAFR. The presence of bacterial lipopolysaccharide activates
natural killer cells (143), where the natural killer cells can then attack the foreign invaders.
Additionally, lipopolysaccharide is a stimulator of monokines, including interleukin 1 (143).
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Molecular functions, enriched in the BROC group, associated include ‘Interleukin-1, type I,
activating receptor activity’ (associated with IL1R1 and IL1RL2), ‘Interleukin-1 receptor
activity’ (associated with IL1RAP, IL1R1, IL1RL, and IL1RAPL2), and ‘Interleukin-1 receptor
binding’ (associated with TLR9, IL1RAP, IL36A, IL36G, IL37, IL36RN, and IL36B). These
predicted biological functions and molecular processes further suggest the potential influence of
BROC intervention to immunity in human infants.
Although we were able to predict the impacts of CRT and BROC intervention on human
infants’ immunity, there are multiple areas within this research that need to be further explored.
In the future, validation of miRNAs and mRNAs expression, using more specific experimental
technique (e.g., quantitative PCR analysis) after BROC and CRT intervention would be
informative. Additionally, studies with larger sample sizes could increase accuracy and provide
better statistical power. We had a sample size of 11 infants, which was a challenge to recruit.
Northwest Arkansas is a collective of multiple, relatively small towns and cities, which had
trouble accepting the invitation for infant participants. We were limited in willing participants,
age-range of participants, and timeframe of the study. In a more populated area, and with more
time, there is a possibility for a large sample size of infants to conduct the study. Lastly, we were
not able to perfectly match macro/micronutrients/fiber contents of the carrot and broccoli purée.
However, both broccoli and carrot contained similar fiber content (BROC = 1.5 g; CRT = 1.6 g).
Given the small differences between them, the fiber intake might have been impacted more by
other factors such as spillage.
While there are a few limitations to our study, there are a few strengths. To our knowledge,
our study is the first attempt that comprehensively profiled fecal miRNAs in response to CRT
and BROC intervention in infant subjects. Additionally, we predicted mRNAs these miRNAs

32

influence through the IPA. In this, we were able to predict the extended potential effects of these
miRNAs may have on the human infants. After, we exposed the vast amounts of predicted
mRNAs to the PANTHER, predicting further into which biological processes and molecular
functions may be impacted. As a result, this allows us to see the potential full affect CRT and
BROC intervention may have on the health of human infants. Lastly, we were able to show that
BROC and CRT intervention both have potential beneficial effects on infant immunity and,
therefore, may help fight against common infant related infections.

Conclusion
In conclusion, we observed 22 miRNAs differentially expressed in CRT intervention, and 20
miRNAs differentially expressed in BROC intervention. When exposed to IPA and PANTHER,
these differentially expressed miRNAs revealed a potential to impact multiple immune related
functions. For example, miR-146a-5p in CRT intervention was predicted to target TLR4, which
may influence biological processes involved with innate and acquired immunity (e.g., Positive
regulation of interleukin-12 biosynthetic process). Additionally, miR-130a-3p in CRT
intervention was predicted to target CSF1, which potentially impacts the innate immune system
through CSF1 involvement in multiple biological processes involving macrophages.
Comparatively, miR-146a-5p in BROC intervention was predicted to target PGLYRP2 and
PGLYRP1. These mRNAs play a role in natural killer cells differentiation, therefore aiding in
the immune systems capability to fight foreign invaders. Overall, our study provides potential
evidence that CRT and BROC intervention impacts human infants’ miRNAs, and may lead to
overall benefits in their immune system.
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Appendix
Table 1. Searched phytochemicals subcategories, sources, and references.1
Phytochemicals
Category:
Subcategory:
Source:
Reference
Acai Berry, Apple, Avocado, Banana,
Blackberry, Blueberry, Cherries,
Cranberry, Currants, Dates, Elderberry,
(144)
Anthocyanidins
Eggplant, Grapes, Grapefruit,
Kiwifruit, Lingonberry, Pomegranate,
Pear, Plum, Nuts, Raspberry,
Strawberry, Tasmanian Peppers, Wine
Apricots, Blackberry, Blueberry,
Cranberry, Coffee, Chocolate, Grape
(144)
Flavone -3-ols
Seeds, Kiwifruit, Nectarines, Nuts,
Peaches, Plums, Rhubarb, Tea, Wine
Flavonoids
Artichokes, Celery Seed Spice, Celery,
Chicory, Honey, Juniper berry,
(144)
Flavones
Kumquats, Oregano, Olive Leaves,
Pumpkin, Parsley, Pimento Peppers,
Sweet Peppers, Sage, Thyme,
Arugula, Asparagus, Bay Leaves,
Capers, Cilantro, Chives, Cherries,
(144)
Flavonols
Cranberries, Dill Weed, Elderberries,
Juniper Berry, Okra, Parsley, Plum,
Prickly, Pears, Saffron, Tarragon
(145)
Isoflavones
Miso, Natto, Soy, Tempeh, Tofu
Apricot, Brussel Sprouts, Cantaloupe,
Carotenes
Cilantro, Kale, Romain Lettuce,
(146)
(pro-vitamin A)
Mango, Orange Pepper, Spinach,
Butternut Squash, Watermelon
Carotenoids
Artichoke, Asparagus, Broccoli, Egg,
Xanthopylls
Kale, Romain Lettuce, Pistachio Nuts,
(146)
(non-pro vitamin
Parsley, Red Pepper, Scallions,
A)
Spinach, Zucchini
Broccoli, Brussel Sprouts, Cauliflower,
(147)
Glucosinolates Isothiocyanates
Cabbage, Kale, Turnips
(148)
Epicholesterol
Nuts, Seeds
Walnuts, Almonds, Peanuts,
(148)
6-Ketochilestanol
Phytosterols
Hazelnuts, Macadamia Nuts
Vegetable Oils, Spelt and Wheat
(148)
Cholesteryl
Cereals
(149)
Organosulfur
Allicins
Garlic, Onions, Leeks
(150)
Compounds
1
The databases PubMed and Google Scholar were utilized for the literature search.
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Figure 1. Food Recall Example
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Figure 2. Study Design Example
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Table 2. Infant participant demographic

Ethnicity

Milk Source
49

Category

Number of Participants

Asian

1

White

3

Native Indian or Alaskan Native & White

1

Asian & White

1

Non -Hispanic or Latino & White

5

Breastfed

8

Formula Fed

3

Both

1

Table 3. Effects of carrot intervention on miRNA
Carrot DEmiR (1.5 Folds; p<0.05)1
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1

miRNA symbol
hsa-miR-1253
hsa-miR-130a-3p

miRBase accession
MIMAT0005904
MIMAT0000425

Avg RQ ± SEM
1.65 ± 0.14
4.85 ± 0.59

P-value vs control
0.017
0.004

hsa-miR-146a-5p

MIMAT0000449

2.38 ± 0.28

0.016

hsa-miR-147a
hsa-miR-193a-3p

MIMAT0000251
MIMAT0000459

2.19 ± 0.36
2.11 ± 0.21

0.043
0.029

hsa-miR-200b-3p

MIMAT0000617

0.38 ± 0.05

0.004

hsa-miR-2116-5p
hsa-miR-300
hsa-miR-3127-5p
hsa-miR-3144-3p
hsa-miR-320a-3p
hsa-miR-365b-5p
hsa-miR-374c-5p
hsa-miR-376b-3p
hsa-miR-378b
hsa-miR-508-5p
hsa-miR-521
hsa-miR-561-5p
hsa-miR-595
hsa-miR-603
hsa-miR-627-5p
hsa-miR-885-3p

MIMAT0011160
MIMAT0004903
MIMAT0014990
MIMAT0015015
MIMAT0000510
MIMAT0022833
MIMAT0018443
MIMAT0002172
MIMAT0014999
MIMAT0004778
MIMAT0002854
MIMAT0022706
MIMAT0003263
MIMAT0003271
MIMAT0003296
MIMAT0004948

0.35 ± 0.11
0.61 ± 0.10
3.13 ± 0.37
1.98 ± 0.22
0.56 ± 0.11
2.84 ± 0.48
2.15 ± 0.36
2.94 ± 0.58
0.13 ± 0.02
0.44 ± 0.16
0.18 ± 0.05
2.06 ± 0.31
2.81 ± 0.49
2.90 ± 0.26
2.19 ± 0.27
0.27 ± 0.13

0.047
0.034
0.010
0.024
0.046
0.031
0.050
0.045
0.035
0.036
0.048
0.038
0.033
0.002
0.040
0.005

Nanosting 2Ingunitive Pathway Analysis (IPA)

Target mRNA2
Not Predicted
ATG2B, CSF1, DICER1, HOXA5, MAFB, MEOX2, SMAD4, TAC1, ZFPM2
ATOH8, BLMH, BRCA1, C8A, CAMP, CCL8, CCNA2, CCR3, CD1D, CD40, CDKN3, CFH, CHUK,
COL13A1, CRP, CXCL8, CXCR4, DMBT1, FADD, IFNA1/IFNA13, IFNB1, IL10, IL12RB2, IL1F10,
IL1R1, IL1RAP, IL1RAPL2¸ IL1RL2, IL36A, IL36B, IL36G, IL36RN, IL37, IRAK1, IRAK2, IRF5,
KIF22, KIR2DL1/KIR2DL3, KIR2DL2, LALBA, LBP, LTB, LTF, MCM10, MCPH1, METTL7A,
MMP16, MR1, NFIX, NLGN1, NOS2, NOVA1, PA2G4, PBLD, PDGFRA, PDIK1L, PEX11G,PGLYR1,
PGLYP2, PLEKHA4, POLE2, PRR15, PTAFR, PTGES2, RAD54L, S100A12, SDCBP2, SFTPD, STAT1,
SYT1, TIMELESS, TLR1, TLR10, TLR4, TLR9, TMSB15A, TRAF6, TRIM14, UHRF1, VWCE
VEGFA
CCND1, E2F6, ERBB4, ESR1, MCL1, PLAU, PTK2, RPS6KB2
ACE2, BAP1, ELMO2, ERBIN, ERRFI1, FHOD1, FOXF2, GEMIN2, GSE1, KLHL20, MARCKS,
PLCG1, PPM1F, PTEN, PTPN12, PTPN13, PTPRD, RERE, WASF3, WDR37, ZEB1, ZEB2, ZFPM2
Not Predicted
Not Predicted
Not Predicted
Not Predicted
HSPB6, TAGLN, VIM
Not Predicted
Not Predicted
Not Predicted
CASP9, IGF1R, ODC1, PDPK1, SUFU, TUSC2
Not Predicted
ERCC8
Not Predicted
Not Predicted
Not Predicted
Not Predicted
Not Predicted

Table 4. Effects of broccoli intervention on miRNA

51
1

miRNA symbol

miRBase accession

Avg RQ ± SEM

hsa-miR-146a-5p

MIMAT0000449

3.07 ± 0.56

hsa-miR-190b
hsa-miR-205-5p
hsa-miR-2116-5p
hsa-miR-22-3p
hsa-miR-329-3p
hsa-miR-361-5p
hsa-miR-3613-3p
hsa-miR-3934-5p
hsa-miR-409-5p
hsa-miR-4425
hsa-miR-4443
hsa-miR-499a-3p
hsa-miR-503-3p
hsa-miR-520f-3p
hsa-miR-548i
hsa-miR-573
hsa-miR-579-5p
hsa-miR-596
hsa-miR-612

MIMAT0004929
MIMAT0000266
MIMAT0011160
MIMAT0000077
MIMAT0001629
MIMAT0000703
MIMAT0017991
MIMAT0018349
MIMAT0001638
MIMAT0018940
MIMAT0018961
MIMAT0004772
MIMAT0022925
MIMAT0002830
MIMAT0005935
MIMAT0003238
MIMAT0026616
MIMAT0003264
MIMAT0003280

2.66 ± 0.46
0.45 ± 0.10
0.32 ± 0.06
2.80 ± 0.44
0.38 ± 0.10
0.21 ± 0.06
0.35 ± 0.05
2.82 ± 0.44
2.31 ± 0.30
0.34 ± 0.06
0.63 ± 0.08
0.45 ± 0.12
0.34 ± 0.07
2.79 ± 0.41
1.97 ± 0.25
3.85 ± 0.84
0.54 ± 0.11
0.22 ± 0.09
1.65 ± 0.17

Broccoli DEmiR (1.5 Folds; p<0.05)1
P-value vs control
Target mRNA2
ATOH8, BLMH, BRCA1, C8A, CAMP, CCL8, CCNA2, CCR3, CD1D, CD40, CDKN3, CFH,
CHUK, COL13A1, CRP, CXCL8, CXCR4, DMBT1, FADD, IFNA1/IFNA13, IFNB1, IL10,
IL12RB2, IL1F10, IL1R1, IL1RAP. IL1RAPL2, IL1RL2, IL36A, IL36B, IL36G, IL36RN, IL37,
IRAK1, IRAK2, IRF5, KIF22, KIR2DL1/KIR2DL3, KIR2DL2, LALBA, LBP, LTB, LTF,
0.037
MCM10, MCPH1, METTL7A, MMP16, MR1, NFIX, NLGN1, NOS2, NOVA1, PA2G4, PBLD,
PDGFRA, PDIK1L, PEX11G, PGLYRP1, PGLYRP2, PLEKHA4, POLE2, PRR15, PTAFR,
PTGES2, RAD54L, S100A12, SDCBP2, SFTPD, STAT1, SYT1, TIMELESS, TLR1, TLR10,
TLR4, TLR9, TMSB15A, TRAF6, TRIM14, UHRF1, VWCE
0.035
Not Predicted
0.038
ATP1A1, DOK4, ERBB3, INPPL1, MED1, PRKCE, PTEN, TRPS1, VEGFA, ZEB1, ZEB2
0.015
Not Predicted
0.034
BMP7, ESR1, MAX, PPARA, SRF
0.017
Not Predicted
0.004
AICDA
0.008
Not Predicted
0.025
Not Predicted
0.036
Not Predicted
0.035
Not Predicted
0.013
Not Predicted
0.034
Not Predicted
0.003
Not Predicted
0.022
Not Predicted
0.048
ERBB2, MTA1
0.047
Not Predicted
0.032
Not Predicted
0.027
Not Predicted
0.031
AKT2, TP53

Nanosting Analysis Results 2Ingunitive Pathway Analysis (IPA) Target mRNA.

Table 5. Signaling prediction of biological process for short-list miRNA in carrot-fed infants

Panther GO Biological Process Terms
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Negative regulation of natural killer cell differentiation
involved in immune response
Negative regulation of natural killer cell differentiation
Positive regulation of cell proliferation by VEGFactivated platelet derived growth factor receptor
signaling pathway
VEGF-activated platelet-derived growth factor receptor
signaling pathway
Growth of symbiont in host
Growth involved in symbiotic interaction
Positive regulation of cellular response to macrophage
colony-stimulating factor stimulus
Positive regulation of response to macrophage colonystimulating factor
Regulation of natural killer cell differentiation involved
in immune response
Receptor biosynthetic process
Regulation of cellular response to macrophage colonystimulating factor stimulus
Regulation of response to macrophage colonystimulating factor
Detection of bacterial lipoprotein
Positive regulation of interleukin-12 biosynthetic
process
Negative regulation of tumor necrosis factor
biosynthetic process

N genes in
reference
genome
dataset

N
genes
in
dataset

Target mRNA
identified in dataset

Fold
Enrichment

P-value

3

2

PGLYRP2, PGLYP1

>100

< 0.001

3

2

PGLYRP2, PGLYP1

>100

< 0.001

3

2

VEGFA, PDGFRA

>100

< 0.001

3

2

CSF1, TLR4

>100

< 0.001

3
3

2
2

PGLYRP2, PGLYP1
PGLYRP2, PGLYP1

>100
>100

< 0.001
< 0.001

3

2

CSF1, TLR4

>100

< 0.001

3

2

CSF1, TLR4

>100

< 0.001

4

2

PGLYRP2, PGLYP1

76.66

< 0.001

5

2

ACE2, IL10

61.33

< 0.001

5

2

CSF1, TLR4

61.33

< 0.001

5

2

CSF1, TLR4

61.33

< 0.001

5

2

DMBT1, TLR1

61.33

< 0.001

8

3

TRAF6, LBT, TLR4

57.49

< 0.001

8

3

IL37, IL10, ERRFI1

57.49

< 0.001

Table 6. Signaling prediction of molecular function for short-list miRNA in carrot-fed infants
N genes in
reference
genome
dataset
2

N genes
in
dataset

Target mRNA identified in dataset

Fold
Enrichment

P-value

2

IL1R1, IL1RL2

>100

< 0.001

7
17

4
8

87.61
72.15

< 0.001
< 0.001

NAD+ nuleotidase, cyclic
ADP-ribose generating
NAD+ nucleosidase activity

16

7

67.08

< 0.001

16

7

67.08

< 0.001

NAD(P)+ nucleosidase activity

16

7

67.08

<0.001

Lipopeptide binding
Platelet-derived growth factor
receptor binding
Pattern recognition receptor
activity
Hydrolase activity, hydrolyzing
N-glycosyl compounds
Lipopolysaccharide binding
Tumor necrosis factor receptor
binding
Growth factor receptor binding

10
15

3
4

IL1RAP, IL1R1, IL1RL2, IL1RAPL2
TLR9, IL1RAP, IL36A, ILF10, IL36G, IL37,
IL36RN, IL36B
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2,
IL1RAPL2, TLR1
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2,
IL1RAPL2, TLR1
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2,
IL1RAPL2, TLR1
TLR1, LBP, CD1D
PTEN, VEGFA, PDGFRA, IL1R1

45.99
40.88

< 0.001
< 0.001

24

6

38.33

< 0.001

38

7

28.24

< 0.001

33
32

6
4

27.88
19.16

< 0.001
< 0.001

136

14

15.78

< 0.001

49

4

12.52

< 0.001

99

7

10.84

< 0.001

Panther GO Molecular Function
Terms
Interleukin-1, type I, activating
receptor activity
Interleukin-1 receptor activity
Interleukin-1 receptor binding
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Tumor necrosis factor receptor
superfamily binding
Cytokine receptor activity

TLR9, DMBT1, PGLYRP2, TLR4, PTAFR,
PGLYRP1
IL1RAP, IL1R1, TLR4, TLR10, ILRL2,
ILRAP2, TLR1
CAMP, DMBT1, TLR4, PTAFR, LTF, LBP
TRAF6, STAT1, LTB, FADD
TRAF6, IL1RAP, IL36A, IL1F10, IL36G,
PTEN, IL37, VEGFA, PDGFRA, ILR1,
ERBB4, IL10, IL36RN, IL36B
TRAF6, STAT1, LTB, FADD
IL12RN2, IL1RAP, CCR3, CXCR4, IL1R1,
IL1RL2, IL1RAPL2

Table 7. Signaling prediction of biological processes for short-list miRNA in broccoli-fed infants

Panther GO Biological Process Terms
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N genes in
reference
genome
dataset

N genes
in
dataset

Target mRNA
identified in dataset

Fold
Enrichment

P-value

3

2

BMP7, STAT1

>100

<0.001

3

2

BMP7, STAT1

>100

<0.001

3

2

PGLYRP2, PGLYRP1

>100

<0.001

3

2

PGLYRP2, PGLYRP1

>100

<0.001

3

2

VEGFA, PDGFRA

>100

<0.001

3

2

VEGFA, PDGFRA

>100

<0.001

3
3

2
2

PGLYRP2, PGLYRP1
PGLYRP2, PGLYRP1

>100
>100

<0.001
<0.001

4

2

PGLYRP2, PGLYRP1

99.29

<0.001

4

2

MED1, ESR1

99.29

<0.001

5

2

DMBT1, TLR1

79.43

<0.001

Metanephric mesenchymal cell proliferation involved in
metanephros development
Kidney mesenchymal cell proliferation
Negative regulation of natural killer cell differentiation
involved in immune response
Negative regulation of natural killer cell differentiation
Positive regulation of cell proliferation by VEGFactivated platelet derived growth factor receptor signaling
pathway
VEGF-activated platelet-derived growth factor receptor
signaling pathway
Growth of symbiont in host
Growth involved in symbiotic interaction
Regulation of natural killer cell differentiation involved
in immune response
Epithelial cell proliferation involved in mammary gland
duct elongation
Detection of bacterial lipoprotein
Branch elongation involved in mammary gland duct
branching
Positive regulation of interleukin-12 biosynthetic process

4

2

MED1, ESR1

79.43

<0.001

7

3

74.47

<0.001

Detection of other organism

14

5

70.09

<0.001

Regulation of interferon-alpha biosynthetic process

6

2

TRAF6, LTB, TLR4
PGLYRP2, TLR4,
PGLYRP1, TLR1,
CD1D
TLR9, IL10

70.09

<0.001

Table 8. Signaling prediction of molecular function for short-list miRNA in broccoli-fed infants
N genes
in
reference
genome
dataset

N
genes
in
dataset

Target mRNA identified in dataset

Fold
Enrichment

P-value

2

2

IL1R1, IL1RAPL2

>100

< 0.001

7

4

IL1RAP, IL1R1, IL1RL, IL1RAPL2

>100

< 0.001

4

2

PGLYP1, PGLYP2

>100

< 0.001

Interleukin-1 receptor binding

17

8

94.35

< 0.001

NAD+ nucleosidase, cyclic
ADP-ribose generating

16

7

86.88

<0.001

NAD+ nucleosidase activity

16

7

86.88

<0.001

16

7

86.88

<0.001

5

2

TLR4, PTAFR

79.43

0.047

5
5

2
2

ERBB3, ERBB2
DMBT1, LBP

79.43
79.43

0.046
0.045

5

2

PGLYP1, PGLYP2

79.43

0.045

10

3

TLR1, LBP, CD1D

59.57

0.004

15

4

PTEN, VEGFA, PDGFRA, IL1R1

52.57

0.004

22

6

TLR9, DMBT1, PGLYRP2, TLR4, PTAFR,
PGLYRP1

49.65

< 0.001

38

8

IL1RAP, MED1, IL1R1, TLR4, TLR10, IL1RL2,
IL1RAPL2, TLR1

41.81

< 0.001

Panther GO Molecular
Function Terms
Interleukin-1, type I,
activating receptor activity
Interleukin-1 receptor activity
N-acetylmuramoyl-L-alanine
amidase activity
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NAD(P)+ nucleosidase
activity
Lipopolysaccharide immune
receptor activity
ErB-3 class receptor binding
Lipoteichoic acid binding
Peptidoglycan immune
receptor regulator
Lipopeptide binding
Platelet-derived growth factor
receptor binding
Pattern recognition receptor
activity
Hydrolase activity,
hydrolyzing N-glycosyl
compounds

TLR9, IL1RAP, IL36A, IL36G, IL37, IL36RN,
IL36B
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, IL1RAPL2,
TLR1
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, IL1RAPL2,
TLR1
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, IL1RAPL2,
TLR1

Supplementary Figure 1. IRB Approval Form
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Supplementary Figure 2. IRB Protocol Approval
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